Show simple item record

dc.contributor.authorFriedlaender, Alex
dc.contributor.authorAddeo, Alfredo
dc.contributor.authorRusso, Alessandro
dc.contributor.authorGregorc, Vanesa
dc.contributor.authorCortinovis, Diego
dc.contributor.authorRolfo, Christian D
dc.date.accessioned2020-09-11T16:41:15Z
dc.date.available2020-09-11T16:41:15Z
dc.date.issued2020-08-31
dc.identifier.urihttp://hdl.handle.net/10713/13686
dc.description.abstractNon-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC.en_US
dc.description.urihttps://doi.org/10.3390/ijms21176329en_US
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofInternational Journal of Molecular Sciencesen_US
dc.subjectALKen_US
dc.subjectEGFRen_US
dc.subjectNSCLCen_US
dc.subjectearly stageen_US
dc.subjectosimertiniben_US
dc.subjecttargeted therapyen_US
dc.titleTargeted Therapies in Early Stage NSCLC: Hype or Hope?en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.doi10.3390/ijms21176329
dc.identifier.pmid32878298
dc.source.volume21
dc.source.issue17
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record